Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DFPP + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral, Extracorporeal
01
Overview
This combination therapy involves the use of Double Filtration Plasmapheresis (DFPP) as an adjunct to the standard-of-care antiviral regimen of peginterferon alfa-2a and ribavirin. DFPP is an extracorporeal blood purification technique that separates plasma from blood cells and then filters the plasma to remove large molecular weight components, including hepatitis C virus (HCV) particles. The rationale is to rapidly reduce the baseline viral load before or during the initiation of antiviral therapy, potentially improving the sustained virologic response (SVR) in patients with genotype 1 chronic hepatitis C and high viral loads. Peginterferon alfa-2a acts as an immunomodulator and antiviral cytokine, while ribavirin is a nucleoside analog that interferes with viral RNA synthesis. This specific protocol was investigated by the National Taiwan University Hospital.
- Other names
- DFPP + Peg-IFN + RBVDouble filtration plasmapheresis + peginterferon alfa-2a + ribavirin
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR (Immune system modulation via type I interferon receptor)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on DFPP + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DFPP + peginterferon alfa-2a + ribavirin.